Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Earnings Results, Misses Estimates By $0.17 EPS

Recursion Pharmaceuticals (NASDAQ:RXRX) released its quarterly earnings data on Friday. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17), Zacks reports. The firm had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.42) earnings per share.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX opened at $7.51 on Friday. The firm has a 50 day moving average of $7.72 and a 200 day moving average of $7.08. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.93 billion, a price-to-earnings ratio of -4.91 and a beta of 0.86. Recursion Pharmaceuticals has a 12-month low of $5.60 and a 12-month high of $14.12.

Wall Street Analyst Weigh In

RXRX has been the subject of a number of analyst reports. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.